Oncternal Therapeutics up as combination therapy for cancer shows promise

Oncternal Therapeutics

12/12/2022 12:37

** Oncternal Therapeutics Inc's shares  ONCT.O  up 2.8% at
$1.1 premarket
        ** Co said on Saturday its experimental drug in
combination with Abbvie  ABBV.N 's cancer drug Imbruvica showed
promise in an ongoing early-stage trial to treat patients with
lymphatic system cancers  urn:newsml:reuters.com:*:nGNXbd9NRZ
  
    ** Nearly 90% of those treated with the combination therapy
showed partial or complete response to therapy, compared with
66% response when treated with only Imbruvica
    ** Up to Friday's close, stock was down ~53% YTD 
 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))